Trial results for the EndoBARR Trial (NCT03694262) investigating the combination of atezolizumab, rucaparib, and bevacizumab for recurrent, progressive endometrial carcinoma were posted on ClinicalTrials.gov on 2025-05-30. The study reported an Overall Response Rate of 30 participants.
Background
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) aimed to demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab, and atezolizumab in recurrent, progressive endometrial carcinoma. The trial included patients with Endometrial Cancer and Uterine Carcinosarcoma.
Trial design
The EndoBARR Trial (NCT03694262) was a Phase 2 study that enrolled 30 participants. The trial investigated the combination of rucaparib, bevacizumab, and atezolizumab in patients with Endometrial Cancer and Uterine Carcinosarcoma, specifically focusing on recurrent, progressive disease.
Key results
The trial results reported on the Overall Response Rate for the treatment group:
- For the outcome titled "Treatment Related Overall Response Rate," the value was 30 participants.
- For the outcome "To Estimate the Overall Response Rate (ORR) of Patients With Progressive/Persistent or Recurrent Endometrial Cancer on Study-directed Therapy, Using the Combination of Rucaparib, Bevacizumab and Atezolizumab," the reported value was 30 Participants.
What this means
The posted results for the EndoBARR Trial provide data on the Overall Response Rate for the combination therapy of atezolizumab, rucaparib, and bevacizumab in patients with recurrent, progressive endometrial carcinoma. These findings contribute to the understanding of this specific combination in this patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03694262, titled "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)," were posted on 2025-05-30 on clinicaltrials.gov.